SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
– Initiated rolling submission of NDA to the FDA for mirdametinib for…
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted…